Teva Pharmaceutical Industries Ltd (ADR) (N:TEVA)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 124 Dvora Hanevi'a St
TEL AVIV-YAFO 6944020
Tel: 1-267-4684475
Website: https://www.tevapharm.com
IR: See website
<
Key People
Richard D. Francis
President, Chief Executive Officer
David Matthew Stark
Executive Vice President, Chief Legal Officer
Eliyahu Sharon Kalif
Chief Financial Officer, Executive Vice President
Galia Inbar
Chief Human Resource Officer and Corporate Affairs, Executive Vice President
Richard Daniell
Executive Vice President - European Commercial
Eric Drape
Executive Vice President - Global Operations
Christine Fox
Executive Vice President - U.S. Commercial
Eric A. Hughes
Executive Vice President, Global R & D, Chief Medical Officer
Mark Sabag
Executive Vice President - International Markets Commercial
Eli Shani
Executive Vice President - Global Marketing and Portfolio
   
Business Overview
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Financial Overview
For the fiscal year ended 31 December 2023, Teva Pharmaceutical Industries Ltd (ADR) revenues increased 6% to $15.85B. Net loss decreased 77% to $559M. Revenues reflect North America segment increase of 9% to $8.12B, Europe segment increase of 7% to $4.84B, International Markets segment increase of 3% to $1.96B. Lower net loss reflects North America segment income increase of 20% to $2.4B.
Employees: 35,001 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $32,596M as of Dec 31, 2023
Annual revenue (TTM): $15,846M as of Dec 31, 2023
EBITDA (TTM): $4,803M as of Dec 31, 2023
Net annual income (TTM): -$559.00M as of Dec 31, 2023
Free cash flow (TTM): $842.00M as of Dec 31, 2023
Net Debt Last Fiscal Year: $16,607M as of Dec 31, 2023
Shares outstanding: 1,120,992,397 as of Feb 18, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.